
BOSTON, Massachusetts — A senior vice president of regulatory affairs at a public biomedical firm has been sentenced to 54 months in federal prison following a guilty plea to securities fraud and illicit insider trading during critical FDA clinical trial reviews.
Incident Overview and Key Developments
Judicial filings established that the defendant liquidated over 220,000 corporate shares through private secondary trust vehicles immediately after receiving non-public notifications that a flagship cardiovascular implant had failed primary safety benchmarks.
- Prosecuting Jurisdiction: District of Massachusetts Federal Court.
- Financial Penalty Imposed: $3.4 million in criminal fines plus $8.9 million in disgorgement.
- Prison Term: 54 months incarceration followed by 3 years supervised release.
Forensic Trading Telematics and Electronic Discovery
Investigators from the SEC Market Abuse Unit utilized automated pattern detection algorithms to cross-reference trading volumes with internal corporate server access timestamps. The analysis confirmed that sell orders were initiated within 42 minutes of the adverse clinical trial memorandum distribution.
| Transaction Date | Shares Liquidated | Realized Price | Loss Avoided |
|---|---|---|---|
| March 14, 2025 | 85,000 Shares | $42.50 / Share | $2.84 Million |
| March 18, 2025 | 135,000 Shares | $41.80 / Share | $4.42 Million |
| Post-Drop Price | 0 Shares | $9.15 / Share | Total Avoided: $7.26M |
Restitution for Harmed Retail Shareholders
The court ordered that all disgorged funds be allocated toward a Fair Fund administered under federal judicial supervision to compensate retail and institutional shareholders who purchased shares during the artificial price inflation window.

